Cardioprotective role of zofenopril in hypertensive patients with acute myocardial infarction: a pooled individual data analysis of the SMILE studies

References

• Pedrinelli R, Ballo P, Fiorentini C, et al. Gruppo di Studio Ipertensione e Cuore, Societa’ Italiana di Cardiologia. Hypertension and acute myocardial infarction: an overview. J Cardiovasc Med (Hagerstown). 2012;13:194–202.
   PubMed Web of Science ®Google Scholar
• Fadl YY, Zareba W, Moss AJ, et al. History of hypertension and enhanced thrombogenic activity in postinfarction patients. Hypertension. 2003;41:943–949.
   PubMed Web of Science ®Google Scholar
• Richards AM, Nicholls MG, Troughton RW, et al. Antecedent hypertension and heart failure after myocardial infarction. J Am Coll Cardiol. 2002;39:1182–1188.
   PubMed Web of Science ®Google Scholar
• Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin. 2004;20:1559–1569.
   PubMed Web of Science ®Google Scholar
• Picariello C, Lazzeri C, Attanà P, et al. The impact of hypertension on patients with acute coronary syndromes. Int J Hypertens. 2011;2011:563657.
   PubMedGoogle Scholar
• Gustafsson F, Torp-Pedersen C, Køber L, et al. Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event. J Hypertens. 1997;15:793–798.
   PubMed Web of Science ®Google Scholar
• Spargias K, Ball S, Hall A. The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy. J Hum Hypertens. 1999;13:511–516.
   PubMed Web of Science ®Google Scholar
• Ambrosioni E. Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am J Cardiovasc Drugs. 2007;7:17–24.
   PubMed Web of Science ®Google Scholar
• Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res. 2005;33:42–54.
   PubMed Web of Science ®Google Scholar
• Borghi C, Bacchelli S, Degli Esposti D. Long-term clinical experience with zofenopril. Expert Rev Cardiovasc Ther. 2012;10:973–982.
   PubMedGoogle Scholar
• Borghi C, Bacchelli S, Degli Esposti D, et al. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opin Pharmacother. 2004;5:1965–1977.
   PubMed Web of Science ®Google Scholar
• Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995;332:80–85.
   PubMed Web of Science ®Google Scholar
• Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J. 2003;145:80–87.
   PubMed Web of Science ®Google Scholar
• Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J. 2007;153:445.e7–14.
   Web of Science ®Google Scholar
• Borghi C, Ambrosioni E, Novo S, SMILE-4 Working Party, et al. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol. 2012;35:416–423.
   PubMed Web of Science ®Google Scholar
• Borghi C, Bacchelli S, Esposti DD, et al. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Hypertens. 1999;12:665–672.
   PubMed Web of Science ®Google Scholar
• Borghi C, Ambrosioni E, Omboni S, SMILE-4 Working Party, et al. Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. J Hypertens. 2013;31:1256–1264.
   PubMed Web of Science ®Google Scholar
• Borghi C, Omboni S, Reggiardo G, et al. Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double-blind, controlled, prospective studies. Open Heart. 2015;2:e000220.
   PubMedGoogle Scholar
• Moyé LA, Pfeffer MA, Wun CC, et al. Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study. Eur Heart J. 1994;15(Suppl.B):2–8.
   PubMed Web of Science ®Google Scholar
• Kostis JB. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens. 1995;8:909–914.
   PubMed Web of Science ®Google Scholar
• Yoshiyama M, Kamimori K, Shimada Y, et al. Left ventricular remodeling after myocardial infarction in antecedent hypertensive patients. Hypertens Res. 2005;28:293–299.
   PubMed Web of Science ®Google Scholar
• Lang CC, Struthers AD. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol. 2013;10:125–34.
   PubMed Web of Science ®Google Scholar
• Rossini R, Senni M, Musumeci G, et al. Prevention of left ventricular remodelling after acute myocardial infarction: an update. Recent Pat Cardiovasc Drug Discov. 2010;5:196–207.
   PubMedGoogle Scholar
• Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev. 2011;16:13–21.
   PubMed Web of Science ®Google Scholar
• Yang JH, Hahn JY, Song YB, et al. Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study. BMJ. 2014;349:g6650.
   PubMed Web of Science ®Google Scholar
• Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–2619.
   PubMed Web of Science ®Google Scholar
• Hansen ML, Gislason GH, Køber L, et al. Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. Br J Clin Pharmacol. 2008;65:217–23.
   PubMed Web of Science ®Google Scholar
• Cacciatore F, Bruzzese G, Vitale DF, et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage, and oxidative stress in hypertensive patients. Eur J Clin Pharmacol. 2011;67:877–883.
   PubMed Web of Science ®Google Scholar
• Napoli C, Bruzzese G, Ignarro LJ, et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J. 2008;156:1154.
   PubMed Web of Science ®Google Scholar
• Omboni S, Malacco E, Parati G. Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions. Cardiovasc Ther. 2009;27:275–288.
   PubMed Web of Science ®Google Scholar
• Frascarelli S, Ghelardoni S, Ronca-Testoni S, et al. Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion. J Cardiovasc Pharmacol. 2004;43:294–299.
   PubMed Web of Science ®Google Scholar
• Pasini AF, Garbin U, Nava MC, et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens. 2007;20:443–450.
   PubMed Web of Science ®Google Scholar
• Przyklenk K, Kloner RA. "Cardioprotection" by ACE-inhibitors in acute myocardial ischemia and infarction? Basic Res Cardiol. 1993;88(Suppl.1):139–154.
   PubMed Web of Science ®Google Scholar